Rss

In the next seven years, the market will be different from the unique vaccine against hepatitis B

In the next seven years, the market will be different from the unique vaccine against hepatitis B

In the next seven years, the market will be different from the unique vaccine against hepatitis B
Employees of the University of Alberta

Come close to creating the final version of the vaccine that works against the main strains of hepatitis C, according to The Vancouver Sun. According to researcher Michael Houghton, a prototype vaccine is being tested in humans. The experiment proved that the vaccine induces an adequate immune response.

There are six major strains of hepatitis C and hundreds of subtypes that infect 170 million people worldwide. The new vaccine, created over 15 years, is made on the basis of only one strain, but leads to the production of antibodies capable of neutralizing a number of other strains.

Initial tests have shown that the vaccine is more effective at higher doses. Despite all the "pros", the development comes to patients only after seven years because of the need to conduct large-scale clinical trials. Maybe in future vaccine can be used in conjunction with standard therapy for the treatment of chronic infection.